Shopping Cart

Your shopping cart is currently empty

Aleglitazar

Name: Aleglitazar
Brand: TargetMol
SKU: T14176
Price: 258 USD
Availability: InStock
Rating: 5 (10 reviews)

🥰Excellent

Catalog No. T14176Cas No. 475479-34-6

Alias RO0728804, R1439

Aleglitazar (R1439) (R1439) is a potent dual PPARα/γ agonist, with IC50s of 38 nM and 19 nM for human PPARa and PPARγ, respectively. Aleglitazar can be used for the research of type II diabetes.

Aleglitazar

🥰Excellent

Purity: 99.03%

Catalog No. T14176Alias RO0728804, R1439Cas No. 475479-34-6

Aleglitazar (R1439) (R1439) is a potent dual PPARα/γ agonist, with IC50s of 38 nM and 19 nM for human PPARa and PPARγ, respectively. Aleglitazar can be used for the research of type II diabetes.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$258	In Stock	In Stock
5 mg	$592	In Stock	In Stock
10 mg	$798	In Stock	In Stock
25 mg	$1,220	In Stock	In Stock
50 mg	$1,650	In Stock	In Stock
100 mg	$2,220	-	In Stock
1 mL x 10 mM (in DMSO)	$598	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products. However, due to objective factors, there is a small probability that the synthesis may not be successful during the R&D process. We appreciate your understanding. If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.

Questions

Batch Information

Select Batch

Purity:99.03%

Resource Download

COA LCMS HNMR

Product Introduction

Bioactivity

Description	Aleglitazar (R1439) (R1439) is a potent dual PPARα/γ agonist, with IC50s of 38 nM and 19 nM for human PPARa and PPARγ, respectively. Aleglitazar can be used for the research of type II diabetes.
Targets&IC50	PPARα:38 nM, PPARγ:19 nM
In vitro	Aleglitazar exhibits species selectivity for PPARα, with EC50 values of 50 nM, 2.26 μM, and 2.34 μM for human, rat, and mouse PPARα, respectively[1]. At concentrations of 0.01-40 μM (12-48 hours), aleglitazar does not significantly increase lactate dehydrogenase (LDH) release at 0.1-20 μM but shows significant increases at 30 μM and 40 μM[2]. Additionally, aleglitazar (0.01-20 μM; 48 hours) decreases hyperglycemia (HG, glucose 25 mM)-induced apoptosis, caspase-3 activity, and cytochrome-C release, while improving cell viability in hyperglycemic conditions[2].
In vivo	Aleglitazar (0.3-3.0 mg/kg; i.p.; daily; for 7 days) exerts beneficial effects on structural and functional outcomes of mild brain ischemia, reduces key aspects of microglia activation including NO production, release of proinflammatory cytokines, migration, and phagocytosis, and attenuates inflammatory responses in the post-ischemic brain[3].
Synonyms	RO0728804, R1439

Chemical Properties

Molecular Weight	437.51
Formula	C₂₄H₂₃NO₅S
Cas No.	475479-34-6
Smiles	C([C@@H](C(O)=O)OC)C1=C2C(=C(OCCC=3N=C(OC3C)C4=CC=CC=C4)C=C1)C=CS2
Relative Density.	1.29
Color	White
Appearance	Solid

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 45 mg/mL (102.85 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.57 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.2857 mL	11.4283 mL	22.8566 mL	114.2831 mL
5 mM	0.4571 mL	2.2857 mL	4.5713 mL	22.8566 mL
10 mM	0.2286 mL	1.1428 mL	2.2857 mL	11.4283 mL
20 mM	0.1143 mL	0.5714 mL	1.1428 mL	5.7142 mL
50 mM	0.0457 mL	0.2286 mL	0.4571 mL	2.2857 mL
100 mM	0.0229 mL	0.1143 mL	0.2286 mL	1.1428 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:

For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments

A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent

DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH₂O. So your working solution concentration is 2 mg/mL。

Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO TargetMol | reagent

(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.

Preparation method for in vivo formula: Take 50 μL DMSO TargetMol | reagent

main solution, add 300 μLPEG300 TargetMol | reagent

mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH₂O TargetMol | reagent

mix well and clarify

For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.

All types of co-solvents required for the protocol, such asDMSO, PEG300/ PEG400, Tween 80, SBE-β-CD, corn oil are available for purchase on the TargetMol website with a simple click.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc